Nerve-Repair injection shows promise for wrist pain
NCT ID NCT06328166
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether an injection of ES135, a lab-made version of a natural growth factor, could help people with carpal tunnel syndrome. Twenty-four adults with confirmed CTS received either ES135 or a placebo injection guided by ultrasound. Researchers tracked changes in symptoms, hand function, and pain over six months to see if the treatment is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ES135 (recombinant human fibroblast growth factor 1)
- What this could lead to
- If it works, this could offer a new injection-based treatment to ease pain and improve hand function in people with carpal tunnel syndrome.
- What could go wrong
- This is a very small, early-stage trial with only 24 participants. The results may not apply to everyone, and the treatment may not prove more effective than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARPAL TUNNEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 325, Sec. 2, Chenggong Rd., Neihu Dist.
Taipei, 114, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A carpal tunnel clue to a silent heart threat?
- Taping technique may offer Drug-Free relief for wrist pain
- One size Doesn't fit all: could pain 'Phenotypes' unlock better carpal tunnel care?
- Ultrasound may reveal hidden clues in carpal tunnel syndrome
- Can a simple tape ease carpal tunnel pain?
- Can a simple tape ease carpal tunnel pain?